E.Merck: Healthy performance - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

E.Merck: Healthy performance

Apr 5, 2002

E.Merck (India), the subsidiary of the German multinational Merck, reported encouraging numbers for the year ended Dec' 01 (FY02). A topline growth of 8% reported by the company is comparatively better than the performance of other MNC pharma peers. Both sales and operating margins improved on the back of upward price revision and relaunch of its vitamin brand Neurobion in June 2000.

(Rs m)FY01FY02%Change
Sales 3,134 3,385 8.0%
Other Income 67 85 26.2%
Expenditure 2,582 2,736 6.0%
Operating Profit (EBDIT) 552 649 17.5%
Operating Profit Margin (%)17.6%19.2%
Interest 23 6 -75.8%
Depreciation 72 95 30.8%
Profit before Tax 524 633 20.8%
Tax 139 186 34.3%
Profit after Tax/(Loss) 385 447 16.0%
Net profit margin (%)12.3%13.2% 
No. of Shares (eoy) (m) 17 17  
Diluted Earnings per share* 22.9 26.5  
P/E (at current price) 12 
(*- annualised)   

E. Merck is a market leader in vitamins and derives over 60% of its turnover from this segment. Three of its vitamin brands Evion, Neurobion and Polybion contribute almost 40% of the company’s turnover. During the first half of the current year the company re-introduced Neurobin with better marketing focus. However, the pharma division showed a sluggish growth of 3% mainly on account of competition from generic players. The slow growth in pharma division was more than compensated by a 20% growth in non-pharma division comprising laboratory and speciality chemicals.

The stock price of the company took a beating last year due to the fact that the government banned manufacture/ marketing of fixed combination of Vitamin B1, B6 and B12 (Neurobin). Besides, the government has been tinkering with this segment with steep price reductions. Such price reductions affected `Polybion`. Coupled with this, the vitamin segment as a whole was not logging any attractive growth rates. As a result, the company had to rework its business strategy by changing formulations and launching `Neurobion Forte`. Further, to overcome the high price volatility in Vitamin E due to fierce competition from Chinese and European suppliers the company is evaluating various options like better utilisation of plant capacity and outsourcing of ingredients.

At the current market price of Rs 325, the stock trades at 12x FY02 earnings. After hitting a low of Rs 240, from a high of Rs 460, the stock price of the company has witnessed a sharp correction in the last few days. The optimism seems to be due to the recent DPCO dilution with most of the vitamin brands coming out of DPCO. E. Merck derives around 60% of its revenues from the vitamin segment. The upsurge in the stock price currently has been on the back of encouraging performance and DPCO expectations. As per the indications, the company has recorded good sale numbers even in the first two months of the current year. However, the product portfolio of the company is still very concentrated and valuations going forward would depend on the success in new therapeutic areas ventured into by the company.

Equitymaster requests your view! Post a comment on "E.Merck: Healthy performance". Click here!

  

More Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO (Views On News)

Jun 15, 2021

All you need to know about the IPO of Krishna Institute of Medical Sciences.

Why Did Shares of Divi's Lab Rally Today? (Views On News)

Jun 10, 2021

The stock jumped 3.6% in intraday trade to hit its 52-week high.

Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

Jun 8, 2021

Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

Jubilant Pharmova Drops 6% on Weak March Quarter Numbers (Views On News)

Jun 8, 2021

Here's a rundown on the latest quarterly results of Jubilant Pharmova.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors (Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

My 'Unlock' Investments (Fast Profits Daily)

Jun 11, 2021

The best unlock investments you can make in the market.

The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

How I Discovered a 400-Year-Old Open Secret to Extreme Wealth (Profit Hunter)

Jun 11, 2021

Charlie Munger's open secret about investing success.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Jun 18, 2021 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS